Longeveron Inc., a clinical-stage biotech company specializing in cellular therapies for rare pediatric and aging-related conditions, will release its Q1 2026 financial results on May 13 after market close. The company will also provide a business update and hold a conference call and webcast at 4:30 p.m. ET the same day. Longeveron's lead product, laromestrocel, targets multiple serious diseases and has received several FDA designations, highlighting its potential. Investors can expect updates on ongoing trials and company progress during the call.
Corporate Insight's report reveals significant differences in virtual assistant performance across eight retirement plan recordkeepers. Fidelity and Voya received top marks for delivering real-time account data, strong natural language processing, an...
Broadcom announced a partnership with Samsung to release the first integrated 5G and Wi-Fi 8 fixed wireless access platform, aiming to improve broadband reliability and efficiency. The company also introduced new Wi-Fi 8 chips for home routers and pa...
Dycom Industries' stock surged 27.95% following its first-quarter report showing a 56.1% year-over-year rise in contract revenue to $1.97 billion, surpassing analyst expectations. The company also raised its fiscal 2027 revenue guidance to $7.38-$7.6...
Imagine, a brand experience firm, has partnered with Bojangles to redesign and enhance the restaurant experience across multiple locations. The collaboration focused on aligning brand strategy with physical design elements like décor and signage to c...
Salesforce, Snowflake, Marvell, and HP are set to report earnings, providing a broad view of AI demand across enterprise software, data cloud, custom silicon, and PCs. Investors are watching for signs that AI-related products and services are driving...
